Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-30T20:05:54.496Z Has data issue: false hasContentIssue false

Purification and refolding of vascular endothelial growth factor-B

Published online by Cambridge University Press:  15 December 2000

SERGIO D.B. SCROFANI
Affiliation:
AMRAD Operations Pty Ltd, 576 Swan Street, Richmond, Victoria, Australia, 3121
LOUIS J. FABRI
Affiliation:
AMRAD Operations Pty Ltd, 576 Swan Street, Richmond, Victoria, Australia, 3121
PING XU
Affiliation:
AMRAD Operations Pty Ltd, 576 Swan Street, Richmond, Victoria, Australia, 3121
PINO MACCARONE
Affiliation:
AMRAD Operations Pty Ltd, 576 Swan Street, Richmond, Victoria, Australia, 3121
ANDREW D. NASH
Affiliation:
AMRAD Operations Pty Ltd, 576 Swan Street, Richmond, Victoria, Australia, 3121
Get access

Abstract

Vascular endothelial growth factor (VEGF)-A interacts with the receptor tyrosine kinases VEGF-R1 and R2, and the importance of this interaction in endothelial cell (EC) function and blood vessel development has been well documented. Other ligands that interact differentially with these receptors and that are structurally related to VEGF-A include VEGF-B, VEGF-C, VEGF-D, and placenta growth factor (PLGF). Compared with VEGF-A, relatively little is known about the biological role of the VEGF-R1 specific ligand, VEGF-B. Two splice variant isoforms that differ at the COOH-terminus and which retain unique solubility characteristics are widely expressed throughout embryonic and postnatal development. Recent analysis of mice with a targeted deletion of the VEGF-B gene has revealed a defect in heart development and function consistent with an important role in vascularization of the myocardium (Bellomo D et al., 2000, Circ Res 86:E29–E35). To facilitate further characterization of VEGF-B, we have developed a protocol for expression and purification of refolded recombinant protein from Escherichia coli inclusion bodies (IBs). The approach developed resolves a number of significant issues associated with VEGF-B, including the ability to heterodimerize with endogenous VEGF-A when co-expressed in mammalian cells, a complex secondary structure incorporating inter- and intrachain disulfide bonds and hydrophobic characteristics that preclude the use of standard chromatographic resins. The resulting purified disulfide-linked homodimer was demonstrated to bind to VEGF-R1 and to compete with VEGF-A for binding to this receptor.

Type
Research Article
Copyright
© 2000 The Protein Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)